April 15, 2021 - The first recruits were injected today to start the Phase I trial of Entos Pharmaceuticals’ made-in-Canada COVID-19 DNA vaccine, Covigenix VAX-001! The Canadian Center for Vaccinology in Halifax, Nova Scotia is conducting the trial.

Like the globally approved mRNA vaccines, Entos’ DNA vaccine delivers the information needed for our cells to make the spike protein to stimulate a protective immune response against SARS-CoV-2.However, Entos’ Covigenix DNA vaccine is more stable at fridge and room temperatures and cheaper to upscale and manufacture millions of doses.

“We need to get 16 billion doses worldwide to beat this pandemic, and we believe DNA is the perfect way to approach that,” said John Lewis, CEO Entos Pharmaceuticals.

Read more about Entos and DNA vaccines from the University of Alberta

Or listen to the podcast SHIFT by Alberta Innovates with Entos Pharmaceuticals CEO John Lewis about the journey to conquer COVID-19. Season 2 - Episode 2